As a result, the tumor suppressive effects of ATRA require the existence of OTUD6B transcripts, which suggests that OTUD6B transcript level can serve as a biomarker to predict whether ATRA would benefit specific ESCC patients. The gene discussed is OTUD6B; the disease is esophageal squamous cell carcinoma.